Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stimuvax plus hormonal therapy vs hormonal therapy alone in post-menopausal ER/PgR-positive advanced breast cancer
2008-005544-17Phase 3Terminated
- Sponsor
- Merck KGaA
- Start
- Jul 2009
- Modality
- Vaccines & Immunotherapeutics, Peptides, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Stimuvax + hormonal treatment with Hormonal treatment alone (plus placebo) (2 arms). Primary endpoint: Progression-free survival time (PFS). Started Jul 2009; status: terminated.
02
Drugs
tecemotide
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-005544-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005544-17.